Registration number: SC259295

Edinburgh Biosciences Ltd.

Contents

Company Information	1
Balance Sheet	2
Notes to the Unaudited Financial Statements	3 to 6
Accountants' Report	7

Edinburgh Biosciences Ltd.

Company Information

Directors

Mr Trevor Wilson Shields Dr Jaswinder Singh Dr Xingcai Sun Mr Ian Dixon Dr Yiyuan Chen Mr Qiang Cheng Mr David James Quigley Miss Xiaole Song Dr Nicola Abraham

Registered office

Unit 4B Gateway Business Park Beancross Road Grangemouth FK3 8WX

Accountants

EQ Accountants Ltd Unit 4B Gateway Business Park Beancross Road Grangemouth FK3 8WX

Edinburgh Biosciences Ltd.

(Registration number: SC259295)
Balance Sheet as at 31 December 2024

	Note	2024 £	2024 £
Fixed assets
Tangible assets	4	6,993	13,561
Current assets
Debtors	5	77,607	287,405
Cash at bank and in hand		125,654	450,669
		203,261	738,074
Creditors: Amounts falling due within one year	6	(319,053)	(546,333)
Net current (liabilities)/assets		(115,792)	191,741
Total assets less current liabilities		(108,799)	205,302
Creditors: Amounts falling due after more than one year	6	(1,133,746)	(245,705)
Net liabilities		(1,242,545)	(40,403)
Capital and reserves
Called up share capital		2,069,930	2,069,930
Share premium reserve		3,230,749	3,230,749
Retained earnings		(6,543,224)	(5,341,082)
Shareholders' deficit		(1,242,545)	(40,403)

For the financial period ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and
•	The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 25 September 2025 and signed on its behalf by:
 

......................................... Mr Trevor Wilson Shields Director

Edinburgh Biosciences Ltd.

Notes to the Unaudited Financial Statements for the Period from 1 April 2024 to 31 December 2024

1	General information

The company is a private company limited by share capital, incorporated in Scotland.

2	Accounting policies

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

It is the opinion of the directors that there is reasonable expectation that the company has adequate resources to continue operations for the foreseeable future. For this reason the going concern basis has been adopted in preparing the financial statements for the period ended 31 December 2024.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Office equipment	Straight line at 25%

Edinburgh Biosciences Ltd.

Notes to the Unaudited Financial Statements for the Period from 1 April 2024 to 31 December 2024

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Financial instruments

Classification
Financial instruments are classified and accounted for, according to the substance of the contractual
arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any
contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
 

3	Employees and Directors

The average number of persons employed by the company (including directors) during the period, was 8 (2024 - 7).

Edinburgh Biosciences Ltd.

Notes to the Unaudited Financial Statements for the Period from 1 April 2024 to 31 December 2024

4	Tangible assets

	Office equipment £	Total £
Cost or valuation
At 1 April 2024	60,407	60,407
Additions	2,245	2,245
At 31 December 2024	62,652	62,652
Depreciation
At 1 April 2024	46,846	46,846
Charge for the period	8,813	8,813
At 31 December 2024	55,659	55,659
Carrying amount
At 31 December 2024	6,993	6,993
At 31 March 2024	13,561	13,561

5

Debtors

Current	2024 £	2024 £
Prepayments	31,292	18,987
Other debtors	46,315	268,418
	77,607	287,405

6

Creditors

Creditors: amounts falling due within one year

	Note	2024 £	2024 £
Due within one year
Loans and borrowings	7	11,055	134,289
Trade creditors		61,136	135,281
Taxation and social security		17,996	30,931
Other creditors		228,866	245,832
		319,053	546,333

Creditors: amounts falling due after more than one year

Edinburgh Biosciences Ltd.

Notes to the Unaudited Financial Statements for the Period from 1 April 2024 to 31 December 2024

	Note	2024 £	2024 £
Due after one year
Loans and borrowings	7	1,133,746	245,705

7	Loans and borrowings

Non-current loans and borrowings

	2024 £	2024 £
Bank borrowings	6,445	13,945
Other borrowings	1,127,301	231,760
	1,133,746	245,705

Current loans and borrowings

	2024 £	2024 £
Bank borrowings	11,055	11,055
Other borrowings	-	123,234
	11,055	134,289

8	Related party transactions

Other creditors include an amount owed to a shareholder of £200,000 (2024: £203,000). Interest was charged on this loan of £9,000 this year (2024: £9,500).

Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
Edinburgh Biosciences Ltd.
for the Period Ended 31 December 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Edinburgh Biosciences Ltd. for the period ended 31 December 2024 as set out on pages 2 to 6 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of ICAS, we are subject to its ethical and other professional requirements which are detailed at http://www.icas.com/accountspreparationguidance.

This report is made solely to the Board of Directors of Edinburgh Biosciences Ltd., as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Edinburgh Biosciences Ltd. and state those matters that we have agreed to state to the Board of Directors of Edinburgh Biosciences Ltd., as a body, in this report in accordance with the requirements of ICAS as detailed at http://www.icas.com/accountspreparationguidance. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Edinburgh Biosciences Ltd. and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Edinburgh Biosciences Ltd. has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and loss of Edinburgh Biosciences Ltd.. You consider that Edinburgh Biosciences Ltd. is exempt from the statutory audit requirement for the period.

We have not been instructed to carry out an audit or a review of the accounts of Edinburgh Biosciences Ltd.. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

EQ Accountants Ltd
Unit 4B
Gateway Business Park
Beancross Road
Grangemouth
FK3 8WX

25 September 2025